Valuation: Simulations Plus, Inc.

Market Cap 371M 320M 301M 274M 515M 35.48B 522M 3.52B 1.38B 17.78B 1.39B 1.36B 59.14B P/E 2026 *
43.7x
P/E 2027 * 40.1x
Enterprise Value 371M 320M 301M 274M 515M 35.48B 522M 3.52B 1.38B 17.78B 1.39B 1.36B 59.14B EV / Sales 2026 *
4.53x
EV / Sales 2027 * 4.3x
Free-Float
83.09%
Yield 2026 *
-
Yield 2027 * -
Current month+0.63%
1 month-0.62%
3 months+39.47%
1 week 15.9
Extreme 15.9
15.9
1 month 15.8
Extreme 15.8
16.1
Manager TitleAgeSince
Chief Executive Officer 67 2018-06-25
Director of Finance/CFO 63 2020-11-30
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 81 1996-07-16
Director/Board Member 58 2014-12-02
Chairman 76 2024-12-16
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 371M
-2.22%+3.41%-15.06%+24.16% 39.6B
-1.68%-0.12%-43.90%+150.98% 13.25B
-1.13%+4.71%-19.54%+64.80% 5.74B
-0.33%+45.52%+34.55% - 3.66B
+0.32%+9.34% - - 2.01B
-3.40%-2.12%+13.70%-43.21% 1.7B
+1.59%-3.77%-39.46% - 967M
+0.86%+1.73%+39.97%+132.02% 924M
-0.82%-0.55%-33.02%-46.28% 836M
Average -0.90%+7.03%-7.85%+47.08% 7.63B
Weighted average by Cap. -1.84%+6.78%-17.54%+53.81%

Financials

2026 *2027 *
Net sales 81.87M 70.68M 66.31M 60.4M 114M 7.83B 115M 777M 305M 3.92B 307M 301M 13.05B 86.26M 74.47M 69.86M 63.63M 120M 8.25B 121M 819M 321M 4.13B 324M 317M 13.74B
Net income 9.53M 8.23M 7.72M 7.03M 13.22M 912M 13.41M 90.52M 35.47M 457M 35.79M 35.02M 1.52B 10.18M 8.79M 8.25M 7.51M 14.12M 973M 14.32M 96.66M 37.88M 488M 38.22M 37.4M 1.62B
Net Debt - -
Logo Simulations Plus, Inc.
Simulations Plus, Inc. specializes in model-informed and artificial intelligence (AI)-accelerated drug development. The Company helps its clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions. The Company’s segments include Software and Services. The Company's Software segment supports pharmaceutical research, development, and commercialization through simulation, modeling, and AI-driven prediction. Its main products include GastroPlus, ADMET Predictor, MonolixSuite, and others for disease modeling and training, as well as Pro-ficiency for clinical operations. Its Services segment includes advanced consulting services across the entire drug development lifecycle. Its scientists and engineers specialize in drug discovery, pharmacokinetics, pharmacodynamics, drug modeling, clinical trial data analysis, regulatory strategy, and medical communications.
Employees
-
Date Price Change
26-08-17 15.90 0.00%
26-08-14 €15.90 0.00%
26-08-13 €15.90 0.00%
26-08-12 €15.90 0.00%
26-08-11 €15.90 0.00%
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
18.35USD
Average target price
17.25USD
Spread / Average Target
-5.99%

Quarterly revenue - Rate of surprise